0001209191-21-031847.txt : 20210511
0001209191-21-031847.hdr.sgml : 20210511
20210511184613
ACCESSION NUMBER: 0001209191-21-031847
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210507
FILED AS OF DATE: 20210511
DATE AS OF CHANGE: 20210511
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scherle Peggy
CENTRAL INDEX KEY: 0001824632
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39527
FILM NUMBER: 21912882
MAIL ADDRESS:
STREET 1: C/O PRELUDE THERAPEUTICS INCORPORATED
STREET 2: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Prelude Therapeutics Inc
CENTRAL INDEX KEY: 0001678660
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811384762
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: (302) 547-3768
MAIL ADDRESS:
STREET 1: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: Prelude Therapeutics Inc.
DATE OF NAME CHANGE: 20160630
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-07
0
0001678660
Prelude Therapeutics Inc
PRLD
0001824632
Scherle Peggy
C/O PRELUDE THERAPEUTICS INCORPORATED
200 POWDER MILL ROAD
WILMINGTON
DE
19803
0
1
0
0
Chief Scientific Officer
Common Stock
2021-05-07
4
M
0
10000
1.43
A
182920
D
Common Stock
2021-05-07
4
S
0
3964
40.2957
D
178956
D
Common Stock
2021-05-07
4
S
0
5836
41.1395
D
173120
D
Common Stock
2021-05-07
4
S
0
200
41.85
D
172920
D
Employee Stock Option (right to buy)
1.43
2021-05-07
4
M
0
10000
0.00
D
2028-11-12
Common Stock
10000
56460
D
Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.67 to $41.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
/s/ Brian Piper, Attorney-in-Fact
2021-05-11